Progress Toward Measles Elimination - Worldwide, 2000-2023.

Anna A Minta, Matt Ferrari, Sebastien Antoni, Brian Lambert, Takudzwa S Sayi, Christopher H Hsu, Claudia Steulet, Marta Gacic-Dobo, Paul A Rota, Mick N Mulders, Alice Wimmer, Anindya Sekhar Bose, Patrick O'Connor, Natasha S Crowcroft
Author Information

Abstract

Measles vaccination effectively prevents measles, a highly contagious disease that can cause severe complications and death and requires high population immunity to interrupt transmission. This report describes measles elimination progress during 2000-2023. During 2000-2023, an estimated 60.3 million measles deaths were averted by vaccination. However, despite commitment from all six World Health Organization regions to eliminate measles, no region has successfully achieved and maintained measles elimination as of the end of 2023. During the COVID-19 pandemic, estimated global coverage with the first dose of measles-containing vaccine (MCV1) declined to 81%, the lowest level since 2008. MCV1 coverage improved to 83% in 2022 but was unchanged in 2023. From 2022 to 2023, estimated measles cases increased 20% worldwide, from 8,645,000 to 10,341,000; the number of countries experiencing large or disruptive outbreaks increased from 36 to 57. Estimated measles deaths decreased 8%, from 116,800 in 2022 to 107,500 in 2023, primarily because an increased number of cases occurred in countries with lower risk for death. The stagnation in MCV1 coverage means millions of children remain unprotected, leading to increases in cases and outbreaks. Coverage with measles-containing vaccine (MCV) is lower, and measles incidence is higher, in low-income countries and countries experiencing fragile, conflict-affected, and vulnerable settings, which exacerbate inequities. Urgent and targeted efforts are needed to ensure that all children receive 2 MCV doses and that surveillance is strengthened to hasten progress toward measles elimination.

References

  1. Lancet Glob Health. 2023 Apr;11(4):e516-e524 [PMID: 36925172]
  2. Stat Med. 2019 Sep 20;38(21):4146-4158 [PMID: 31290184]
  3. Vaccines (Basel). 2024 Jul 22;12(7): [PMID: 39066457]
  4. MMWR Morb Mortal Wkly Rep. 2023 Nov 17;72(46):1262-1268 [PMID: 37971951]
  5. Lancet. 2024 May 25;403(10441):2307-2316 [PMID: 38705159]
  6. Vaccines (Basel). 2024 Aug 22;12(8): [PMID: 39204069]

MeSH Term

Humans
Measles
Disease Eradication
Measles Vaccine
Global Health
Child, Preschool
Child
Infant
Disease Outbreaks
Adolescent
Vaccination Coverage
COVID-19
Incidence

Chemicals

Measles Vaccine

Word Cloud

Created with Highcharts 10.0.0measles2023countrieselimination2000-2023estimatedcoverageMCV12022casesincreasedMeaslesvaccinationdeathprogressdeathsmeasles-containingvaccine000numberexperiencingoutbreakslowerchildrenMCVeffectivelypreventshighlycontagiousdiseasecancauseseverecomplicationsrequireshighpopulationimmunityinterrupttransmissionreportdescribes603millionavertedHoweverdespitecommitmentsixWorldHealthOrganizationregionseliminateregionsuccessfullyachievedmaintainedendCOVID-19pandemicglobalfirstdosedeclined81%lowestlevelsince2008improved83%unchanged20%worldwide864510341largedisruptive3657Estimateddecreased8%116800107500primarilyoccurredriskstagnationmeansmillionsremainunprotectedleadingincreasesCoverageincidencehigherlow-incomefragileconflict-affectedvulnerablesettingsexacerbateinequitiesUrgenttargetedeffortsneededensurereceive2dosessurveillancestrengthenedhastentowardProgressTowardElimination-Worldwide

Similar Articles

Cited By